Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

13.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neogenomics Inc

< Previous 1 2 3 4 5 6 Next >
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D 
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- NeoGenomics, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Reports Revenue of $117 Million in the First Quarter
First-Quarter 2022 Results - Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% - Clinical Services revenue increased 2%... 
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies FORT MYERS, FL / ACCESSWIRE / April... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – NEO
From The Rosen Law Firm, P.A.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of NeoGenomics, Inc. (NEO) Investors
From Kirby McInerney LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO
From Labaton Sucharow LLP
Via Business Wire
NeoGenomics Announces CEO Departure and Initiates CEO Search
Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc.... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.